The outlook of companies tied to Sildenafil's legacy presents a challenging investment scenario . While the initial surge generated substantial returns , generic copies have significantly diminished revenue. Investing in related pharmaceutical businesses now requires a discerning assessment of proprietary protection , evolving healthcare trends , a